Relief Therapeutics Holding SA
Relief Therapeutics Holding SA (RLFTF): 8 pipeline candidates · ~3 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.7 months
0% dilution
Lead: Phase 2/Phase 3
8 candidates
N/A
N/A
A transparent, data-derived signal for Relief Therapeutics Holding SAacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.2M
Cash
$14.6M
Quarterly Burn
$17.6M
Runway
2.7 mo
Revenue
$6.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| anu ice | — |
| electropulse | — |
| electropulse - low back pain | — |
| electropulse-cosmetic | — |
| light relief | — |
| pq grass | Phase 2/Phase 3 |
| rp-008 | Phase 1/Phase 2 |
| varenicline | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in Relief Therapeutics Holding SA's pipeline?
Relief Therapeutics Holding SA (RLFTF) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Relief Therapeutics Holding SA's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Relief Therapeutics Holding SA has approximately 2.7 months of cash runway.
What is Relief Therapeutics Holding SA's market capitalization?
Relief Therapeutics Holding SA's market capitalization is approximately $4.2M.
Who is the CEO of Relief Therapeutics Holding SA?
Mr. Zachery W. Henderson is the chief executive officer of Relief Therapeutics Holding SA (RLFTF).
Get the full picture on Relief Therapeutics Holding SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.